The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

Long-Term Follow-up of Pancreatic Cancer Patients with Lung Metastasis Using Integrated Cancer Treatment: A Case Report

통합암치료를 적용한 폐전이 동반 췌장암 환자의 장기간 추적관찰 증례보고

  • Received : 2023.08.23
  • Accepted : 2023.10.02
  • Published : 2023.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: This long-term case report details a case of pancreatic cancer with lung metastasis suppressed by integrative cancer medicine (IMT). Methods: A 64-year-old woman diagnosed with pancreatic cancer visited a Korean medicine hospital complaining about the side effects of chemotherapy for lung metastasis. She received IMT involving Korean traditional medicine and Western immunotherapy from May 2017 to June 2023. Tumor dimensions were assessed through computed tomography (CT) and positron-emission tomography/CT scans, while tumor markers and safety were monitored by laboratory tests. Results: IMT suppressed the progression of cancer, as observed by imaging and laboratory tests. The patient achieved 5-year survival, even after discontinuing chemotherapy. Conclusion: This case presents a potential therapeutic alternative for patients who are ineligible for chemotherapy or surgical interventions.

Keywords

References

  1. NIH. Cancer Stat Facts: Pancreatic Cancer. Available from:https://seer.cancer.gov/statfacts/html/pancreas.html Accessed 19th September 2023.
  2. Jung KW, Won YJ, Kang MJ, Kong HJ, Im JS, Seo HG. Prediction of Cancer Incidence and Mortality in Korea. Cancer Res Treat 2022;54(2):345-51. https://doi.org/10.4143/crt.2022.179
  3. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020;52(2):335-50. https://doi.org/10.4143/crt.2020.206
  4. Committee of the Korean clinical practice guideline for pancreatic cancer and National Cancer Center, Korea. Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. Pancreatology 2021;21(7):1326-41. https://doi.org/10.1016/j.pan.2021.05.004
  5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25. https://doi.org/10.1056/NEJMoa1011923
  6. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med 2013;369(18):1691-703. https://doi.org/10.1056/NEJMoa1304369
  7. Han GJ, Jeong HY, Park EJ, Lee AR, Lee JM, Seong S, Kim SS. Review of Domestic Research on Korean Medicine for Pancreatic Cancer. J Int Korean Med 2019;40(1):70-88. https://doi.org/10.22246/jikm.2019.40.1.70
  8. Ko EB, Jang KJ, Jang JY, Song MH, Shin KS. A Case Report of Partial Remission of End-stage Pancreatic Cancer Patient with Liver Metastasis Treated with Chemotherapy and Integrated Medicine Therapy. J Int Korean Med 2020;41(2):166-76. https://doi.org/10.22246/jikm.2020.41.2.166
  9. Bang SH, Lee JH, Cho JH, Lee YW, Son CG, Cho CK, et al. A Case Report of Pancreatic Cancer Treated with Lymph Node Metastasis. Korean J Orient Int Med 2007;28(4):948-55.
  10. Joo HE, Kim JW, Park JH, Cho YM, Seo HS, Ko EJ, et al. A Case Report of Traditional Korean Medicine Based-Integrative Oncology of Recurrent Pancreatic Cancer. J of Kor Traditional Oncology 2022;27(1):1-12.
  11. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet 2020;395(10242):2008-20. https://doi.org/10.1016/S0140-6736(20)30974-0
  12. Yoon HC, Kang JY, Kim JY, Joung JY, Son CG, Lee NH, et al. Trends in Treatment with and Mechanism of Moxibustion in Cancer Patients: A Review. J Int Korean Med 2015;36(3):361-79.
  13. Guo JQ, Zheng QH, Chen H, Chen L, Xu JB, Chen MY, et al. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE-cadherin/EphA2/MMP9/MMP2 expression. Int J Oncol 2014;45(3):1065-72. https://doi.org/10.3892/ijo.2014.2500
  14. Bang JY, Kim EY, Shim TK, Yoo HS, Lee YW, Kim YS, et al. Analysis of anti-angiogenic mechanism of HangAmDan-B(HAD-B), a Korean traditional medicine, using antibody microarray chip. J Biochip 2000;4(4):350-5. https://doi.org/10.1007/s13206-010-4412-5
  15. Kim JM, Park JW, Yoo HS, Lee YW, Cho CK. Case Report of the Pancreatic Cancer Patient after Pancreatoduodenectomy who is Taking the HangAm-Plus to Anti-metastasis and Preventing Recurrence. J of Kor Traditional Oncology 2011;16(1):33-9.
  16. Bottger F, Valles-Marti A, Cahn L, Jimenez CR. High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer. J Exp Clin Cancer Res 2021;40(1):343.
  17. Thronicke A, Schad F, Debus M, Grabowski J, Soldner G. Viscum album L. Therapy in Oncology: An Update on Current Evidence. Complement Med Res 2022;29(4):362-8. https://doi.org/10.1159/000524184
  18. Wei Y, Zhang Y, Li P, Yan C, Wang L. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. Int Immunopharmacol 2023;117:109744.